Genetic studies of ASD implicate alterations in synaptic development and signaling, with the synaptic protein neurexin-1 playing a pivotal role. Ann Marie Craig aims to develop new approaches to overcome neurexin-1-linked synaptic deficits in ASD by modulating the remaining NRXN1 allele to boost neurexin-1 function and restore synaptic structure and function.
SFARI is pleased to announce that it intends to fund 15 grants in response to the Winter 2019 Pilot Award request for applications (RFA).
SFARI is pleased to announce that it has selected four awardees in response to the 2018 Bridge to Independence Award request for applications. This program helps early-career scientists transition from mentored training positions to independent careers in autism research.
Peng Zhang is an assistant professorCase Western Reserve University. He studies the role of HS 3-O-sulfation in neurexin-ligand binding and its effect on synaptic function in autism mouse models.
The Innovative Medicines Initiative, a European public-private initiative, recently awarded a €115 million five-year grant for autism research. The Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials) brings together 48 partners from academia, industry and nonprofit foundations, including SFARI.
Paul Wang, Deputy Director of Clinical Research Associates, L.L.C. (CRA), discusses the research that CRA supports, including human and animal studies using arbaclofen, a potential drug treatment for autism.
Rebecca Saxe will test whether midbrain dopaminergic signals of social cravings, previously observed in mice, are similarly observed in humans. As impairments in social motivation have been postulated to be a core social deficit in autism spectrum disorder (ASD), these results will improve the value of the mouse model for testing mechanisms of altered social motivation in ASD.
Evan Feinberg is an assistant professor in the Department of Anatomy and a member of the Kavli Institute for Fundamental Neuroscience and the Center for Integrative Neuroscience at the University of California, San Francisco.
He received his undergraduate degree in biochemical sciences at Harvard University, where he worked with Craig Hunter on the molecular mechanisms underlying systemic spread of RNA interference in C. elegans. His doctoral studies were conducted at The Rockefeller University in the laboratory of Cori Bargmann, where he developed GRASP (GFP Reconstitution Across Synaptic Partners), a method that enables in vivo visualization of synapses between defined neurons.
Feinberg pursued postdoctoral training at Harvard University with Markus Meister, where he performed the first two-photon calcium imaging study of the superior colliculus and discovered its columnar functional architecture. The Feinberg lab studies sensorimotor integration using optical, genetic and behavioral methods in mice and has received research support from the E.M. Ziegler, Brain & Behavior Research and the Whitehall Foundation in addition to receiving a Klingenstein-Simons Fellowship Award.
- Previous Page
- Viewing
- Next Page